XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $2M invested in XTL Biopharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 2 → 4 (+2)
0% more ownership
Funds ownership: 4.73% → 4.74% (+0%)
18% less capital invested
Capital invested by funds: $2.45M → $2M (-$452K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.13K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$737 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.03K |
XTLB Hedge Fund Activity: Q3 2015 in Review
4 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2015, worth a combined $2M — down 18% from $2.45M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XTLB positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $3.13K. The largest seller was Sabby Management, cutting an estimated $2.03K.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2015, up from 2 in Q2 2015.
- Funds reported $2M of XTL Biopharmaceuticals stock for Q3 2015, down 18% quarter-over-quarter.
- 2 funds opened new XTL Biopharmaceuticals positions in Q3 2015 and 0 closed out, a net change of +2 holders.
- The largest XTL Biopharmaceuticals buyer in Q3 2015 was UBS Group, an estimated $3.13K added.
- The largest XTL Biopharmaceuticals seller in Q3 2015 was Sabby Management, an estimated $2.03K sold.
Based on aggregated 13F filings for Q3 2015.